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11 Abstract This review is designed to systematically examine
12 the available evidence about virtual reality exposure therapy’s
13 (VRET) efficacy for phobias, critically describe some of the
14 most important challenges in the field and discuss possible
15 directions. Evidence reveals that virtual reality (VR) is an
16 effective treatment for phobias and useful for studying specific
17 issues, such as pharmacological compounds and behavioral
18 manipulations, that can enhance treatment outcomes. In addi-
19 tion, some variables, such as sense of presence in virtual en-
20 vironments, have a significant influence on outcomes, but
21 further research is needed to better understand their role in
22 therapeutic outcomes. We conclude that VR is a useful tool
23 to improve exposure therapy and it can be a good option to
24 analyze the processes and mechanisms involved in exposure
25 therapy and the ways this strategy can be enhanced. In the
26 coming years, there will be a significant expansion of VR in
27 routine practice in clinical contexts.
28 Keywords Virtual reality . Mixed realities . Psychological
29 treatments . Phobias interventions . Systematic review
30Introduction
31Virtual reality (VR) is a technology that makes it possible to
32generate “analogues” of the real world. It consists of
33computer-generated worlds that can be practically indistin-
34guishable from the real world. Through this technology, it is
35possible to create artificial experiences in real time, making
36the user feel immersed and able to interact as if it were the real
37world. VR can generate new forms of human-machine inter-
38action, as the media become part of ourselves, extensions of
39the senses [1]. VR users come to believe that the experience is
40real and that they are really there. VR’s capacity to make users
41feel like they are in a certain place and having meaningful
42experiences raises numerous possibilities for psychology [2,
433].
44Currently, VR is considered an effective tool for the treat-
45ment of many psychological problems [4]. These potential
46uses are related to two advantages of VR: the control it allows
47and its great flexibility. Creating virtual worlds provides great
48possibilities that can even surpass reality. Moreover, the user
49will always be safe and protected in these synthetic worlds.
50Since the first publications in the early 1990s, numerous
51clinical trials have been carried out, and reviews and meta-
52analytic studies have provided evidence about VR’s useful-
53ness for various clinical conditions (e.g., anxiety disorders,
54stress-related disorders, psychosis, eating disorders, and
55health conditions). In particular, VR’s efficacy has been most
56striking in the area of phobias, especially in carrying out ex-
57posure therapy. Exposure therapy is considered the “gold stan-
58dard” evidence-based technique for these disorders, but it may
59be difficult to accept and is sometimes rejected by patients
60because they consider it too aversive. VR exposure therapy
61(VRET) can overcome or mitigate this problem by producing
62greater user acceptance and providing control and access to
63situations where exposure therapy would be uncontrollable
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64 (fear of flying); difficult to access (open spaces, being far from
65 home, going to another country in an agoraphobic patient); or
66 simply inaccessible (fear of ghosts, specific past or future
67 situations). VRET is not considered a new form of therapy,
68 but rather a technological adjunct [5] that can help the clini-
69 cian to apply treatments more ecologically and effectively [6].
70 This paper aims to address the following objectives: exam-
71 ine the available evidence about VRET efficacy for phobias
72 published in the past 5 years through a systematic review,
73 critically describe some of the most important achievements
74 and challenges in the field, and discuss possible future per-
75 spectives for VRET developments in Clinical Psychology.
76 Findings regarding augmented reality (AR), a tool that blends
77 both virtual and real-world elements, are also considered for
78 this study.
79 Method
80 Study Selection
81 The PRISMA guidelines for systematic reviews and meta-
82 analyses were employed to conduct a literature search [7].
83 All studies on VRET for phobias in the past 5 years were
84 included in the first scope of the search criteria. Randomized
85 control trials (RCT) were included following these criteria: (1)
86 participants had a diagnosis of a phobia, (2) VRET was ap-
87 plied to intervene on the clinical symptoms, (3) there were at
88 least ten participants in each experimental condition, (4) arti-
89 cles were published in English or Spanish, and (5) articles
90 were published in peer-reviewed journals.
91 Data Sources and Searches
92 Major medical, health, and psychological literature databases,
93 including PsycNet, PubMed, Scopus, and Web of Science,
94 were utilized. Search criteria included all publications from
95 2012 to January 2017. Although the entry style for keywords
96 was modified depending on the requirements of each data-
97 base, the following keywords were used: “virtual reality ex-
98 posure therapy” OR “virtual reality” OR “augmented reality”
99 combined with phob* OR arachnophobia OR “social anxiety
100 disorder” OR agoraphobia OR “fear flying” OR acrophobia
101 OR “fear of falling.”
102 Systematic and narrative reviews, meta-analyses, proto-
103 cols, case studies, studies on change processes and mecha-
104 nisms, and any other sources of evidence (theoretical or em-
105 pirical) were retrieved and classified into categories to update
106 the cutting-edge research in the field. However, all these arti-
107 cles were excluded from the principal analysis based on the
108 systematic review of RCT on the efficacy or effectiveness of
109 VRET for phobias.
110Upon completion of the search, titles and abstracts of the
111identified articles were assessed for suitability for the review.
112Then, full texts of the suitable articles were retrieved for fur-
113ther examination of their contents. The reference lists of the
114selected articles, as well as previous systematic reviews and
115meta-analyses, were also examined for additional publications
116that might have been overlooked in the search. Titles and
117abstracts of all the papers identified through the search were
118read. The full texts of studies that appeared to meet the inclu-
119sion criteria were then independently reviewed and screened
120by two researchers to establish their relevance, in addition to
121studies with insufficient information in the title and abstract.
122Any discrepancies between the researchers were resolved
123through discussion and final agreement.
124Results
125Virtual Reality Exposure Efficacy
126Meta-analysis and Reviews
127In the last 5 years, one meta-analysis on VRET efficacy was
128conducted [8]. This study doubled the total number of partic-
129ipants from previous studies [9, 10] and incorporated new
130methodological tools for data analysis, although with a limi-
131tation regarding the small sample size. Recently, another
132meta-analysis has been conducted [11••], but focusing on the
133generalizability of the results to real-life situations. This study
134used an innovative approach, incorporating only those studies
135that included behavioral tests and, thus, trying to avoid self-
136report biases. Finally, Ling, Nefs, Morina, Heynderickx, and
137Brinkman [12••] presented the first meta-analysis on the rela-
138tionship between sense of presence and anxiety during VRET,
139confirming a positive relationship between them. The study’s
140main strength lies in presenting moderators that may be useful
141for clinical application.
142With regard to systematic reviews, two studies [13, 14]
143presented data coinciding with previous evidence, showing
144the overall efficacy of VRET and providing a broader scope
145because not only phobias were included. However, Turner and
146Casey [13] included few studies and failed to incorporate an
147important moderator, such as the sense of presence in VR. A
148major limitation of Valmaggia et al. [14] stems from the rather
149limited qualitative synthesis of the studies included. All these
150studies showed a clear superiority of VRET versus non-active
151control groups, and equal or even slightly greater efficacy than
152other active control groups (mainly in vivo exposure within a
153CBT protocol). Despite all these efforts, not all meta-analyses
154and reviews achieve high-quality standards [6]. It must be
155pointed out that a further systematic review focused on AR
156was conducted within the last 5 years [15]. It constitutes the
157first review that examines the use of AR in psychological
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158 disorders. All the studies conducted with AR are on phobias
159 and although AR seems to be a promising tool, the field is still
160 in its infancy to establish conclusive statements.
161 Randomized Controlled Trials in the Past 5 Years
162 The search resulted in 124 citations, of which 97 were not
163 considered relevant for this review. A description of the pro-
164 cess followed and reasons for excluding studies are presented
165 in the flowchart (Fig. 1). A total of 27 articles were selected
166 after examination of the abstracts. Following an in-depth anal-
167 ysis of the full text, 11 of them met the inclusion criteria. The
168studies were conducted in different countries: one in the USA
169[16], one in Canada [20], three in Spain [18•, 35, 36], one in
170France [32], two in the Netherlands [22•, 29], one in Rumania
171[31], one in Italy [37], and one in Australia [25].
172As Table 1 shows, a total of 11 RCTs [16, 18•, 20, 22•, 25,
17329, 31, 32, 35–37] analyzing the efficacy of VRETwere car-
174ried out. Ten studies focused on VR and only one used a
175variant of VR (augmented reality). As for the disorders ad-
176dressed, three studies focused on social anxiety disorder [16,
17720, 22•]; five on agoraphobia (including or not panic disorder)
178[25, 29, 32, 35, 36]; one on small animal phobia [18•]; one on
179different phobias (social anxiety disorder, flying phobia, and
Fig. 1 Identifying relevant works: flow chart of systematic review and reasons for inclusion and exclusion
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180 acrophobia) [31]; and one on fear of flying [37]. In all of them,
181 the experimental conditions for comparison were evidence-
182 based treatments and were compared to active conditions or
183 a waiting list (WL). The sample size was small in all studies,
184 and no sub-sample exceeded 35 participants. Regarding other
185 methodological issues, Table 1 presents the specific items on
186 the CONSORT checklist for each RCT.
187 Overall, VRET conditions showed to be significantly more
188 efficacious than non-active control conditions (WL). This is
189 the case for all disorders and all studies, except from panic
190 disorder in which only one study was conducted [32] showing
191 no significant differences between conditions. It is interesting
192 to point out that this study is one of the few ones that is
193 constituted by a large sample which is one of the major flaws
194 in the field and thus it may be an explanatory factor of the
195 absence of differences.
196 With respect to the overall comparison of VRETconditions
197 to active conditions, there is a pattern that shows no significant
198 differences between the conditions taking into consideration
199 diverse active conditions and a number of mental disorders,
200 with just few exceptions. This is consistent with the principal
201 aim of VR treatments. That is, not to greatly surpass the effect
202 sizes of traditional approaches but to equal the effects taking
203 into account the vast array of advantages that VRETentail and
204 explained elsewhere, for example [6]. Bouchard et al. [20] is
205 the only study presenting findings in favor of VRET condi-
206 tion. On the contrary, just Kampmann et al. [22•], Botella et al.
207 [18•], and Meyerbröker et al. [29] present results in favor of
208 the in vivo condition. Nevertheless, there are vital differences
209 between the studies to be stressed. While Kampmann’s study
210 [22•] tends to lessen the results (the follow-up shows a signif-
211 icant difference in favor of in vivo), Botella’s study [18•]
212 shows to be equally efficacious in the follow-up measure-
213 ments and Meyerbröker’s study [29] only presents results fa-
214 voring in vivo condition above VRET condition in one out of
215 four measures. Besides, Botella’s study [18•] has been con-
216 ducted utilizing AR which may behave in a different way
217 compared to VR. In any case, all these conclusions must be
218 taken with caution and thus quantitative meta-analytical stud-
219 ies should test these descriptive assumptions.
220 Relevant Issues and Challenges of VR
221 Sense of Presence and Treatment Outcomes
222 The sense of presence in VR environments has been inten-
223 sively researched, but there has been considerable discussion
224 about its definition (e.g., [38–44]). As Diemer et al. [45] point-
225 ed out, theories of presence can be divided into descriptive and
226 structural models. Descriptive models focus on delimitating
227 the components of presence (e.g., [46, 47]). From this per-
228 spective, presence has been considered a multidimensional
229 construct that includes different aspects, such as spatial
230presence, social presence, co-presence, involvement, realness,
231and so on. By contrast, structural models focus on explaining
232how presence is generated in users (e.g., [48, 49]).
233In spite of this controversy, many authors have suggested
234that this illusion is a key ingredient in achieving success in
235VRET [9, 50–53]. However, research on the influence of pres-
236ence on treatment outcome has produced mixed results. Krijn
237et al. [54] manipulated presence using a head-mounted display
238(HMD) (low presence) or a computerized automatic virtual
239environment (CAVE) (high presence), finding no differences
240between the two conditions in the efficacy of VRET for acro-
241phobia. However, this study did not assess presence directly,
242but instead only manipulated it [55]. In fact, the authors found
243that participants who dropped out early experienced less pres-
244ence and did not feel anxiety in the virtual environment, com-
245pared to completer patients. Price and Anderson [56] reported
246similar results for fear of flying: presence contributed to the
247experience of anxiety, and it was associated with peak fear
248ratings during the first VRET session, but they did not find a
249relationship between presence and treatment response. They
250concluded that sense of presence may be a necessary but in-
251sufficient variable for successful VRET. However, this study
252assessed presence using a unidimensional measure [55].
253Hence, they [55] examined the associations between presence
254(and its constituents: spatial presence, involvement, realness);
255fear ratings; and treatment response in a social phobia sample.
256Findings showed that global presence and the realness factor
257were related to fear scores. Nevertheless, spatial presence did
258not show associations with fear scores or treatment response.
259Finally, only the involvement factor significantly predicted
260treatment response. As involvement is related to attention to
261the environment, the authors suggested that these results
262agreed with proposed mechanisms of exposure therapy, dem-
263onstrating that sustained attention during exposure is associ-
264ated with better treatment responses [55].
265Because experiencing anxiety is considered a key requisite
266for effective exposure therapy, many authors have suggested
267that presence-treatment outcome relationships could be influ-
268enced by presence-anxiety correlations. However, studies
269show unclear relationships between presence and emotions.
270Some studies found significant positive correlations, [56, 57],
271some did not [54, 58, 59], and some even found negative
272correlations [60, 61]. Ling et al.’s meta-analysis [12] exam-
273ined the relationship between presence and anxiety during
274VRET, identifying 33 papers with a total of 1.196 participants.
275They also examined potential moderators (characteristics of
276the technology, sample, disorder, and study design). This
277meta-analysis confirmed the positive relationship between
278presence and anxiety, and that this relationship is influenced
279by several moderating factors (with a large relationship for
280fear of animals and fear of flying, moderate for acrophobia,
281and small for social anxiety disorder). In addition, presence-
282anxiety correlations were stronger for clinical populations
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283than for non-clinical populations. Finally, moderating effects
284were found for some technology characteristics.
285Although significant correlations between presence and
286anxiety have been reported, it remains unclear why they are
287related [62]. It is not clear whether users’ pre-existing anxiety
288increases their likelihood of feeling present or if an anxiety-
289inducing virtual environment enhances presence. A causal
290influence of fear or anxiety on presence has been suggested
291[63], and also has been highlighted the importance of emo-
292tional responses in presence [64]. Peperkorn et al. [62] ana-
293lyzed the temporal dynamics in the interplay of presence-anx-
294iety, and whether this relationship may change over the course
295of VRET trials. They found that, initially, presence influenced
296fear, suggesting a causal role for presence in the experience of
297fear in early stages of VRET. However, presence and fear were
298mutually dependent over time, and a reciprocal dependency
299was found between the two as VRET continued. High immer-
300sion and high presence also seemed to be important during
301initial VRET sessions. This study also showed a relevant role
302of stereoscopy compared to monoscopy, in fearful
303participants. These results coincide with a meta-analysis [65]
304examining the effect of immersive system technology on pres-
305ence: aggregating effect sizes of 83 studies, these authors con-
306cluded that technological immersion had a medium-sized
307effect.
308In conclusion, although presence seems to be an important
309factor in inducing anxiety and fear and achieving a successful
310treatment outcome, more research is needed to better under-
311stand how these factors interact and clarify the causal relation-
312ship between presence and fear in VRET. As this relationship
313is better understood, it will probably influence virtual environ-
314ment designs for therapeutic uses.
315VR-based Exposure Therapy Enhancement
316As mentioned above, exposure therapy has been shown to be
317efficacious in the treatment of anxiety disorders; however,
318there is still room for improvement, and several lines of re-
319search have been devoted to enhancing exposure therapy out-
320comes by means of pharmacological compounds or the mod-
321ulation of behavioral parameters [66]. Enhanced therapeutic
322outcomes has been defined [67] as greater reductions in symp-
323tom severity, greater response rates at post treatment and
324follow-up assessments, significant improvement earlier in
325treatment, or treatment outcomes obtained in less time.
326One way to increase therapeutic outcomes in exposure
327therapy is to use cognitive enhancers, medications that en-
328hance the neurological circuitry of fear extinction and can
329augment the efficacy of exposure therapy. For example, D-
330cycloserine (DCS) enhances fear extinction because it is a
331partial agonist of the glutamatergic N-methill-D-aspartate
332(NMDA) receptors. DCS is the most widely tested cognitive
333enhancer, but others have been used to support exposure
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334 therapy: yohimbine hydrochloride (YHCL), glucocorticoids
335 and cortisol (G-CORT), and brain-derived neurotrophic factor
336 (BDNF). The results indicate that cognitive enhancers can
337 improve therapeutic outcomes in exposure therapy, with
338 within-session fear habituation and between-session fear
339 learning being key issues in enhancing fear extinction or, by
340 contrast, reconsolidating existing fear memories. In summary,
341 cognitive enhancers can be a safe and easy option to increase
342 the effects of exposure therapy (for more information, see [67,
343 68, 69•].
344 Using VR can be a good option in studies where it is im-
345 portant to explore the processes and mechanisms involved in
346 exposure therapy. When the target is testing a specific effect
347 (e.g., to expedite treatment gains), it is important to have com-
348 plete control over the variables involved in the exposure pro-
349 cess, and VR can be an excellent choice (provides complete
350 control over the cues presented and related parameters such as
351 time, distance, size, etc.). Therefore, it is not surprising that
352 some studies exploring the utility of cognitive enhancers have
353 been conducted using VR. Specifically, two studies [70, 71]
354 tested the utility of DCS in the treatment of acrophobia. Two
355 other studies tested the use of other cognitive enhancers in
356 specific phobias, YHCL in aerophobia [72], and G-CORT in
357 acrophobia [73].
358 The second line of research focused on the enhancement of
359 fear extinction through the modulation of behavioral parame-
360 ters, such as multiple contexts, mass extinction, or concurrent
361 exciters. Again, VR allows a highly controlled context manip-
362 ulation, and it helps to induce contextual shifts during the
363 VRETsession. An interesting study [74••] explored the effects
364 of multiple contexts in spider phobia using several VR con-
365 texts, and their results showed that multiple contexts enhance
366 exposure therapy’s generalizability. These results reveal the
367 clinical utility of VR. If changing the context is important in
368 exposure therapy, VR is an excellent option to expose patients
369 to different contexts without leaving the consultation room. In
370 in vivo exposure, shifting contexts would be more time con-
371 suming and costly.
372 Additionally, a further study [75] explored the differential
373 role of perceptual versus conceptual cues (fear-related
374 information) in fear activation/reduction in claustrophobia
375 and spider phobia. Results showed that perceptual cues pro-
376 duced higher fear activation and greater fear habituation.
377 These findings point to the potential of VR in controlling the
378 manipulation of perceptual cues to enhance exposure therapy.
379 These authors have also used VR to explore other features,
380 such as fear reactivation prior to exposure therapy [76] or size
381 estimation in spider phobia [77]. These studies found no effect
382 of fear reactivation prior to exposure on treatment outcomes,
383 and they showed that size estimation is biased in spider pho-
384 bia, but this bias is corrected with exposure therapy.
385 In summary, VR is a good way to conduct exposure ther-
386 apy, but also to study specific issues, such as pharmacological
387compounds and behavioral manipulations, that can enhance
388treatment outcomes.
389Discussion and Conclusions
390This review followed the structured PRISMA guidelines.
391Eleven studies were identified that fulfilled the selection
392criteria and contained potentially useful information about
393the efficacy of VRET for the treatment of phobias. As in
394previous meta-analyses [9, 10], the results further confirm
395VRET’s potential in treating these problems. These studies
396have demonstrated that VR used in conjunction with tradition-
397al evidence-based psychological treatments can provide inno-
398vative treatment strategies for this problem.
399However, somemethodological issues should be taken into
400consideration. First, the sample sizes were small. This point
401was already highlighted [78], with the impact this may have
402on reaching erroneous conclusions [79, 80]. Second, there was
403a lack of studies carried out in clinical settings. All the studies
404were conducted in controlled research contexts, which makes
405it difficult to detect the degree of feasibility of VRET in natural
406clinical settings. Thus, it is necessary to carry out effectiveness
407and cost effectiveness studies in different delivery contexts
408(hospitals, private practices). The third issue is the data anal-
409ysis. Statistical procedures that allow more precise investiga-
410tions of mechanisms of change/causal mechanisms, such as
411multilevel regression analysis, are also lacking, although prog-
412ress is already being made in this regard [22•]. Fourth, more
413attention should be paid to the CONSORT guidelines. As
414Table 2 reveals, only four studies provided a registration num-
415ber, and only one study described how sample size was deter-
416mined. Finally, it would be highly advisable for studies to
417report on dropouts and possible side effects.
418Regarding the sociodemographic characteristics of partici-
419pants, the majority were women and adult populations, then
420more studies with children and elderly populations are neces-
421sary. This could be due to the accessibility of the samples. In
422the case of children, in addition, there are ethical limitations
423because they require informed consent from parents, and the
424use of technologies is sometimes perceived as risky. However,
425paradoxically, children and the elderly are populations for
426which VR may be particularly useful because of the total
427control (and protection for participants) VR provide. In addi-
428tion, in the case of children, a clear advantage is the possibility
429of incorporating aspects related to serious games (computer-
430ized games for serious purposes) and gamification (gaming
431elements used outside of games) that make it possible to de-
432signmore attractive and engaging interventions [81]; although
433this might be true for all populations, in children it may be
434especially useful [82, 83]. Fortunately, some recent work [84•]
435stresses the importance of using VR to enhance children’s
436lives by creating compelling experiences [84•, 85]. As for
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t2:1 Table 2 CONSORT 2010 checklist
t2:2 Section/topic Item no. Checklist item Studies including
item (n = 11)
t2:3 Title and abstract
t2:4 1a Identification as a randomized trial in the title 8
t2:5 1b Structured summary of trial design, methods, results, and conclusions
(for specific guidance see CONSORT for abstracts)
6
t2:6 Introduction
t2:7 Background and objectives 2a Scientific background and explanation of rationale 11
t2:8 2b Specific objectives or hypotheses 9
t2:9 Methods
t2:10 Trial design 3a Description of trial design (such as parallel, factorial) including
allocation ratio
8
t2:11 3b Important changes to methods after trial commencement (such as
eligibility criteria), with reasons
0
t2:12 Participants 4a Eligibility criteria for participants 11
t2:13 4b Settings and locations where the data were collected 8
t2:14 Interventions 5 The interventions for each group with sufficient details to allow r
eplication, including how and when they were actually administered
9
t2:15 Outcomes 6a Completely defined pre-specified primary and secondary outcome
measures, including how and when they were assessed
4
t2:16 6b Any changes to trial outcomes after the trial commenced, with reasons 0
t2:17 Sample size 7a How sample size was determined 1
t2:18 7b When applicable, explanation of any interim analyses and stopping guidelines 0
t2:19 Randomisation:
t2:20 Sequence generation 8a Method used to generate the random allocation sequence 9
t2:21 8b Type of randomisation; details of any restriction (such as blocking
and block size)
4
t2:22 Allocation concealment mechanism 9 Mechanism used to implement the random allocation sequence
(such as sequentially numbered containers), describing any steps
taken to conceal the sequence until interventions were assigned
5
t2:23 Implementation 10 Who generated the random allocation sequence, who enrolled
participants, and who assigned participants to interventions
5
t2:24 Blinding 11a If done, who was blinded after assignment to interventions (for example,
participants, care providers, those assessing outcomes) and how
2
t2:25 11b If relevant, description of the similarity of interventions 1
t2:26 Statistical methods 12a Statistical methods used to compare groups for primary and
secondary outcomes
10
t2:27 12b Methods for additional analyses, such as subgroup analyses and
adjusted analyses
8
t2:28 Results
t2:29 Participant flow (a diagram is strongly
recommended)
13a For each group, the numbers of participants who were randomly
assigned, received intended treatment, and were analyzed for
the primary outcome
11
t2:30 13b For each group, losses and exclusions after randomisation,
together with reasons
9
t2:31 Recruitment 14a Dates defining the periods of recruitment and follow-up 4
t2:32 14b Why the trial ended or was stopped 0
t2:33 Baseline data 15 A table showing baseline demographic and clinical characteristics
for each group
3
t2:34 Numbers analyzed 16 For each group, number of participants (denominator) included in
each analysis and whether the analysis was by original assigned groups
11
t2:35 Outcomes and estimation 17a For each primary and secondary outcome, results for each group,
and the estimated effect size and its precision (such as 95%
confidence interval)
9
t2:36 17b For binary outcomes, presentation of both absolute and relative
effect sizes is recommended
3
t2:37 Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses
and adjusted analyses, distinguishing pre-specified from exploratory
9
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437 older adults, as Grenier et al. [86] show, exposure therapy for
438 late-life anxiety presents difficulties, and VR can be useful to
439 overcome this obstacle. In any case, new published clinical
440 protocols ensure the ongoing development of this research
441 domain, applied to specific clinical conditions, such as dental
442 [87] or spider phobia [88].
443 A second aim of this work was to identify possible relevant
444 issues and challenges of VR in this field. Progress has been
445 made in studying the possible relationship between presence
446 and treatment outcomes. However, further research is still
447 needed to obtain useful information about interactions and/or
448 causal relationships that can guide us in developing new ap-
449 plications and in establishing guidelines for conducting VRET
450 in clinical practice.
451 Moreover, several experimental studies have demonstrated
452 the usefulness of VR in exploring hypotheses related to the
453 processes and mechanisms involved in exposure therapy be-
454 cause of the high degree of control that this technology allows.
455 In the same vein, several studies have shown that VR can be
456 an excellent choice to study important factors related to fear
457 activation/reduction in the lab, and to generate useful innova-
458 tions for developing new treatment strategies to enhance ther-
459 apeutic outcomes.
460 Technological advances, such as VR, entail new forms of
461 human-machine interactions that may cause potential prob-
462 lems, and ethical issues should be taken into consideration.
463 A major topic addressed two decades ago was cyber-
464 sickness and after-effects of treatment due to the VR system
465 itself. In those first years, there was also a concern about the
466 appropriateness of utilizing VR in specific populations (e.g.,
467 PTSD, personality disorders, children, elderly population),
468 and there has been no evidence of harmful effects of
469 implementing a VR system. However, this does not mean that
470 VR cannot lead to some kind of iatrogenic effect. Negative
471effects and deterioration can occur in VR just like in other
472psychological interventions. For instance, one study [89] fo-
473cused on the negative effects among participants receiving
474Internet-based CBT and reported an average deterioration of
4755.8 and 17.4% in the control conditions. These data are quite
476similar to those obtained in face-to face psychotherapy, and
477comparable to the deterioration rate (between 5 and 10%)
478reported by Lambert [90]. It would be extremely important
479to identify the extent to which VR treatments lead to
480deterioration.
481It is also necessary to debate the direction that techno-
482logical advances in the clinical field should take. Ongoing
483developments should be guided by a main principle, the
484personalization of health care. To do so, it is important to
485find out for whom certain applications can be more use-
486ful, in what contexts, and with what application specifi-
487cations. These ideas coincide with other recent voices em-
488phasizing the need to develop the next generation of
489VRET [91•] and reach the greatest number of people
490[92]. To accomplish this, it would be useful to combine
491several available technologies (e.g., VR, Internet, mobile
492devices, sensors, etc.) and “Big Data” possibilities [93].
493Likewise, it is necessary to promote research in different
494cultural contexts, particularly in low-income countries
495where much less research is conducted, but even more
496psychological problems exist (e.g., [94]).
497Finally, due to space limitations, other relevant themes
498have not been addressed. First, there is a possibility of using
499“virtual bodies and selves,” virtual self-representations, and
500especially “autonomous doppelgangers” [95] to influence at-
501titudes, emotions, and behavior. As Bailenson [96] points out,
502they will also allow us to have abilities that were not possible
503before. Researchers are just beginning to understand the im-
504plications and possibilities of these technologies. In the near
t2:38 Table 2 (continued)
Section/topic Item no. Checklist item Studies including
item (n = 11)
t2:39 Harms 19 All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)
2
t2:40 Discussion
t2:41 Limitations 20 Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
9
t2:42 Generalisability 21 Generalisability (external validity, applicability) of the
trial findings
7
t2:43 Interpretation 22 Interpretation consistent with results, balancing benefits
and harms, and considering other relevant evidence
11
t2:44 Other information
t2:45 Registration 23 Registration number and name of trial registry 4
t2:46 Protocol 24 Where the full trial protocol can be accessed, if available 4
t2:47 Funding 25 Sources of funding and other support (such as supply
of drugs), role of funders
7
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505 future, these studies will provide many theoretical answers
506 and practical applications for many fields, including phobia
507 treatment, but this area of research also involves several ethi-
508 cal considerations that should be seriously considered.
509 Second, studies have also investigated whether using technol-
510 ogy such as VR can have a negative influence on the thera-
511 peutic alliance and, thus, on treatment outcomes. The data
512 indicate that the relationship between patient and therapist
513 are similar to what is observed in traditional face-to-face ther-
514 apy. In any case, the recommendation would be to further
515 explore this issue and use therapeutic alliance measures in
516 clinical contexts where VRET is used, such asWAI-VAR [97].
517 This study has several limitations. First, no protocol was
518 published to conduct this systematic review. Second, the au-
519 thors of the studies were not contacted to obtain further infor-
520 mation about ongoing, unpublished studies/manuscripts, and
521 to complete some missing data from the primary studies that
522 were not provided in the available articles. Finally, the quality
523 assessment of primary studies was not reported study by
524 study, but rather an overall table for CONSORT criteria is
525 presented.
526 Conclusions
527 VRET applications have become an effective alternative
528 that can equal the results of traditional treatments for pho-
529 bias from an efficacy point of view. However, they are
530 also tools capable of enhancing the psychological treat-
531 ment field. In the coming years, there will be a significant
532 increase in the routine use of these VRET applications in
533 clinical contexts, but first there are important challenges
534 to overcome. The most important is the acceptance of
535 these technologies by clinicians. This acceptance will be
536 associated with an additional reduction in costs, the de-
537 velopment of easy-to-use devices, and the implementation
538 of actions and programs to train the clinician. VR appli-
539 cations can be very useful for the treatment of phobias. In
540 order to progress in this field, new research lines should
541 find the best strategies to enhance exposure therapy, re-
542 duce the recurrence of fear, and increase the acceptability
543 of exposure-based treatments. As stated above, VR appli-
544 cations are not a new form of therapy; however, they are a
545 crucial element that can revolutionize the current Clinical
546 Psychology field and contribute to creating a new portfo-
547 lio of delivery models [92], helping us to “reboot” psy-
548 chotherapy research and clinical practice and reduce the
549 burden of mental illness.
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